Exclusive Summary

• Validated Efficacy & Safety: Demonstrated high histological clearance rates in Phase II trials (89% for isSCC, 100% for BCC) with an excellent safety profile and no SAEs.
• Clear FDA Regulatory Pathway: Successfully completed FDA Type C meeting (April 2024), securing agreement for a Pivotal Phase 3 study design with a reduced sample size of 380 patients.
• Superior Cosmetic Outcomes: Offers a non-surgical alternative that eliminates scarring risk, providing a significant cosmetic advantage over the standard of care (surgical excision).
• Proprietary Delivery Platform: Built on exclusive global patent-protected PNP (HKP) siRNA delivery technology, ensuring stability and targeted cell penetration via NRP1 receptors.

Asset Materials

Contact Us for Full Materials